HLA Ligand Profiles of Primary Renal Cell Carcinoma Maintained in Metastases

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2009 Feb 3

PMID 19184600

Citations 34

Authors

Juliane Sarah Stickel

Andreas O Weinzierl

Nina Hillen

Oliver Drews

Mathias M Schuler

Jorg Hennenlotter

Dorothee Wernet

Claudia A Muller

Arnulf Stenzl

Hans-Georg Rammensee

Stefan Stevanovic

Affiliations

Soon will be listed here.

Abstract

In recent years, several approaches have been taken in the peptide-based immunotherapy of metastatic renal cell carcinoma (RCC), although little is known about HLA presentation on metastases compared to primary tumor and normal tissue of RCC. In this study we compared primary tumor, normal tissue and metastases with the aim of identifying similarities and differences between these tissues. We performed this comparison for two RCC patients on the level of the HLA ligandome using mass spectrometry and for three patients on the level of the transcriptome using oligonucleotide microarrays. The quantitative results show that primary tumor is more similar to metastasis than to normal tissue, both on the level of HLA ligand presentation and mRNA. We were able to characterize a total of 142 peptides in the qualitative analysis of HLA-presented peptides. Six of them were significantly overpresented on metastasis, among them a peptide derived from CD151; fourteen were overpresented on both primary tumor and metastasis compared to normal tissue, among them an HLA ligand derived from tumor protein p53. Thus, we could demonstrate that peptide-based immunotherapy might affect tumor as well as metastasis of RCC, but not healthy kidney tissue. Furthermore we were able to identify several peptides derived from tumor-associated antigens that are suitable for vaccination of metastatic RCC.

Citing Articles

Prognostic Significance of Gene Variants and Expression in Renal Cell Carcinoma.

Chang C, Bao B, Hsueh Y, Chen P, Chang L, Li C Biomedicines. 2024; 12(8).

PMID: 39200159 PMC: 11351164. DOI: 10.3390/biomedicines12081694.

Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma.

Wang S, Li Y, Lin Y, Li J, Guo L, Wang H Sci Rep. 2024; 14(1):11985.

PMID: 38796629 PMC: 11127953. DOI: 10.1038/s41598-024-62738-0.

A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma.

Pandey K, Wang S, Mifsud N, Faridi P, Davenport A, Webb A Front Oncol. 2023; 13:1192448.

PMID: 37637064 PMC: 10455951. DOI: 10.3389/fonc.2023.1192448.

Crystal structures of MHC class I complexes reveal the elusive intermediate conformations explored during peptide editing.

Li L, Peng X, Batliwala M, Bouvier M Nat Commun. 2023; 14(1):5020.

PMID: 37596268 PMC: 10439229. DOI: 10.1038/s41467-023-40736-6.

Unusual crystal structures of MHC class I complexes reveal the elusive intermediate conformations explored during peptide editing in antigen presentation.

Li L, Peng X, Batliwala M, Bouvier M Res Sq. 2023; .

PMID: 36747752 PMC: 9901037. DOI: 10.21203/rs.3.rs-2500847/v1.

References

Weinzierl A, Lemmel C, Schoor O, Muller M, Kruger T, Wernet D . Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics. 2006; 6(1):102-13. DOI: 10.1074/mcp.M600310-MCP200. View

Warburton H, Brady M, Vlatkovic N, Linehan W, Parsons K, Boyd M . p53 regulation and function in renal cell carcinoma. Cancer Res. 2005; 65(15):6498-503. DOI: 10.1158/0008-5472.CAN-05-0017. View

Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C . Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004; 63(4):651-5. DOI: 10.1016/j.urology.2003.11.011. View

Zoller M . Gastrointestinal tumors: metastasis and tetraspanins. Z Gastroenterol. 2006; 44(7):573-86. DOI: 10.1055/s-2006-926795. View

Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker H . Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol. 2004; 22(4):450-4. DOI: 10.1038/nbt947. View

Tokuhara T, Hasegawa H, Hattori N, Ishida H, Taki T, Tachibana S . Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res. 2001; 7(12):4109-14. View

Kruger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J . Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother. 2005; 54(9):826-36. PMC: 11032929. DOI: 10.1007/s00262-004-0650-5. View

Weinzierl A, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O . A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 2008; 68(7):2447-54. DOI: 10.1158/0008-5472.CAN-07-2540. View

Wierecky J, Muller M, Wirths S, Halder-Oehler E, Dorfel D, Schmidt S . Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66(11):5910-8. DOI: 10.1158/0008-5472.CAN-05-3905. View

10.

Yao M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, Ishiguro H . Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 2005; 205(3):377-87. DOI: 10.1002/path.1693. View

11.

Uzunlar A, Sahin H, Yilmaz F, Ozekinci S . Expression of p53 oncoprotein and bcl-2 in renal cell carcinoma. Saudi Med J. 2005; 26(1):37-41. View

12.

Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O . Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002; 62(20):5818-27. View

13.

Rammensee H, Weinschenk T, Gouttefangeas C, Stevanovic S . Towards patient-specific tumor antigen selection for vaccination. Immunol Rev. 2002; 188:164-76. DOI: 10.1034/j.1600-065x.2002.18815.x. View

14.

Kohno M, Hasegawa H, Miyake M, Yamamoto T, Fujita S . CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer. 2002; 97(3):336-43. DOI: 10.1002/ijc.1605. View

15.

Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee H . Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother. 2006; 56(1):117-28. PMC: 11030119. DOI: 10.1007/s00262-006-0172-4. View

16.

Yanez-Mo M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa M . Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions. J Cell Biol. 1998; 141(3):791-804. PMC: 2132738. DOI: 10.1083/jcb.141.3.791. View

17.

Stevanovic S . Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer. 2002; 2(7):514-20. DOI: 10.1038/nrc841. View

18.

De Mulder P, van Herpen C, Mulders P . Current treatment of renal cell carcinoma. Ann Oncol. 2004; 15 Suppl 4:iv319-28. DOI: 10.1093/annonc/mdh946. View

19.

Glaspy J . Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002; 29(3 Suppl 7):41-6. DOI: 10.1053/sonc.2002.33083. View

20.

Mombini H, Givi M, Rashidi I . Relationship between expression of p53 protein and tumor subtype and grade in renal cell carcinoma. Urol J. 2007; 3(2):79-81. View